gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.


MART-1, Melan-A
This gene is a retrotransposon-derived, paternally expressed imprinted gene that is highly expressed at the late fetal stage in both the fetus and placenta. It has an overlapping maternally expressed antisense transcript, which contains several microRNAs targeting the transcripts of this gene through an RNA interference (RNAi) mechanism. This gene is essential for maintenance of the fetal capillaries. [provided by RefSeq, Jul 2009] (from NCBI)
Top mentioned proteins: Artemis, S-100, CAN, HAD, tyrosinase
Papers using MART-1 antibodies
Generation of Th1-Polarizing Dendritic Cells Using the TLR7/8 Agonist CL075
Geiger Christiane et al., In Journal of Translational Medicine, 2005
... The unlabelled CCR7 (clone 2H4) antibody (Becton Dickinson) and the MART-1/Melan-A antibody (clone A103; Dako Cytomation, Hamburg, Germany) were ...
Preservation of eumelanin hair pigmentation in proopiomelanocortin-deficient mice on a nonagouti (a/a) genetic background
Bröcker Eva-B. et al., In Journal of Skin Cancer, 2004
... ], Melan-A (clone A103, Dako, Denmark) [ ...
High proliferative activity may predict early metastasis of thin melanomas
de-Almeida Oslei P. et al., In Medicina Oral, Patología Oral y Cirugía Bucal, 2000
... with Permanent Red (Permanent Red Substrate System, Dako) for the primary antibodies S-100, HMB-45 and Melan-A, and diaminobenzidine hydrochloride (DAB, Dako) was used as chromogen ...
Studies on experimental malignant nerve sheath tumor maintained in tissue and organ culture system
Rubin Brian P et al., In Rare Tumors, 1975
... Gown), tyrosinase (T311, 1:100, Novocastra, Norwell, MA), Melan-A (A103, 1:200, DAKO, Carpinteria, CA, USA), and ...
Papers on MART-1
Comparison of MITF and Melan-A Immunohistochemistry During Mohs Surgery for Lentigo Maligna-Type Melanoma In Situ and Lentigo Maligna Melanoma.
Arpey et al., Rochester, United States. In Dermatol Surg, Feb 2016
Melan-A is a cytoplasmic melanocyte immunostain useful on frozen sections but may lack specificity.
Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines.
Demicheli et al., Belo Horizonte, Brazil. In Eur J Med Chem, Feb 2016
In vitro cytotoxic activities against cancerous (human chronic myelogenous leukemia, K562 and murine metastatic melanoma, B16F10) and healthy non-cancerous (murine fibroblasts, L929 and murine melanocytes, Melan-A) cells showed that, compared to free ligands, both of the metal complexes are more active as anticancer agents at low concentration in cancerous cell lines, but also possessed toxic effect at comparatively higher concentration towards the non-cancerous cells.
Enhanced expression of melanoma progression markers in mouse model of sleep apnea.
Fiori et al., Rio Grande, Brazil. In Rev Port Pneumol (barc), Feb 2016
Immunohistochemistry staining for Ki-67, PCNA, S100-beta, HMB-45, Melan-A, TGF-beta, Caspase-1, and HIF-1alpha were quantified using Photoshop.
Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia.
Oliva, Boston, United States. In Mod Pathol, Jan 2016
There is variable positivity for HMB-45, MelanA, MiTF, and CathepsinK, and some tumors have been shown to express TFE-3 especially when associated with "clear cell" morphology.
HMB-45 negative angiomyolipoma of the orbit: a case report and review of the literature.
Liu et al., Taipei, Taiwan. In Bmc Ophthalmol, Dec 2015
PEComas share overlapping histopathological features with epithelioid cells along a perivascular distribution and characteristic immunohistochemistry with coexpression of myoid and melanocytic markers (HMB-45 /or Melan-A).
A rare case of amelanotic malignant melanoma in the oral region: Clinical investigation and immunohistochemical study.
Kakudo et al., Ōsaka, Japan. In Oncol Lett, Dec 2015
The expression of three melanocytic differentiation markers, HMB-45, S-100 and Melan-A, was also measured in primary oral AMMs in order to determine whether the markers could be used to diagnose primary oral AMMs and to find out which marker was the most sensitive.
Spitz nevus arising in the eyelid of a teenager.
Yoon et al., Philadelphia, United States. In Surv Ophthalmol, Nov 2015
HMB-45, MART-1, and microphthalmia-associated transcription factor were all positive and established the melanocytic nature of the benign tumor.
MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics.
Mehra et al., Ann Arbor, United States. In Arch Pathol Lab Med, Oct 2015
Directed ancillary testing is an essential aspect to the workup of t-RCC cases and may include a panel of immunohistochemical stains, such as PAX8, pancytokeratins, epithelial membrane antigen, carbonic anhydrase IX, HMB-45, and Melan-A.
Laryngeal primary malignant melanoma: a case report.
BălŢătescu et al., Constanţa, Romania. In Rom J Morphol Embryol, 2014
Immunohistochemical stains were strongly positive for S-100 protein, HMB-45 and Melan-A.
Hepatic falciform ligament clear cell myomelanocytic tumor: A case report and a comprehensive review of the literature on perivascular epithelioid cell tumors.
Zhou et al., Qingdao, China. In Bmc Cancer, 2014
Histological and immunohistochemical analysis revealed the main transparent epithelioid cells and smooth muscle spindle cells to be HMB-45(+), smooth muscle actin(+), and melan-A (+).
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
Chen et al., Princeton, United States. In J Clin Oncol, 2014
High pretreatment NY-ESO-1 and MART-1-specific CD8(+) T cells were associated with progression of disease.
Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells.
Kawamoto et al., Yokohama, Japan. In Cell Stem Cell, 2013
In this study, we established iPSCs from mature cytotoxic T cells specific for the melanoma epitope MART-1.
Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.
Hoon et al., Santa Monica, United States. In J Clin Oncol, 2012
Blood was assessed using a verified multimarker RT-qPCR assay (MART-1, MAGE-A3, and GalNAc-T) of melanoma-associated proteins.
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis.
Pawelec et al., Tübingen, Germany. In J Clin Oncol, 2012
The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma.
HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
Jotereau et al., Nantes, France. In J Immunol, 2012
The modified melan-A long peptides (not their wild-type counterparts) give rise to highly sustained cross-presentation capacity by monocyte-derived dendritic cells and could be used as tumor vaccines for treatment of melanoma patients.
MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro.
Mordoh et al., Buenos Aires, Argentina. In J Invest Dermatol, 2012
MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro.
Aberrant Melan-A expression in atypical fibroxanthoma and undifferentiated pleomorphic sarcoma of the skin.
Brenn et al., Edinburgh, United Kingdom. In J Cutan Pathol, 2011
Aberrant expression of Melan-A and MART-1 in AFX and undifferentiated pleomorphic sarcoma of the skin represents an important diagnostic pitfall with potential for misdiagnosis as melanoma.
Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells.
Teillaud et al., Buenos Aires, Argentina. In Plos One, 2011
naturally occurring MART-1 melanoma antigen can be taken-up from dying melanoma cells into DC or MAK and both cell types can induce specific CD8(+) T cell cross-presentation thereafter.
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes.
Melief et al., Leiden, Netherlands. In Nat Immunol, 2011
Nardilysin and TOP were required, either together or alone, for the generation of a tumor-specific CTL epitope from PRAME, an immunodominant CTL epitope from Epstein-Barr virus protein EBNA3C, and a clinically important epitope from the melanoma protein MART-1.
share on facebooktweetadd +1mail to friends